Mesoblast (MESO) Free Cash Flow Growth (3y) (2019 - 2023)
Mesoblast (MESO) Free Cash Flow Growth (3y) (2019 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Mesoblast | 18.89 Bn | 18.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -6.55% |
| Mar 31, 2023 | 6.52% |
| Dec 31, 2022 | -131.28% |
| Sep 30, 2022 | 2.80% |
| Jun 30, 2022 | 10.04% |
| Mar 31, 2022 | 9.86% |
| Dec 31, 2021 | -122.26% |
| Sep 30, 2021 | 2.35% |
| Jun 30, 2021 | 2.14% |
| Mar 31, 2021 | -7.67% |
| Dec 31, 2020 | -27.18% |
| Sep 30, 2020 | -11.43% |
| Jun 30, 2020 | 16.52% |
| Mar 31, 2020 | 8.15% |
| Dec 31, 2019 | 62.66% |
| Sep 30, 2019 | 9.26% |
| Jun 30, 2019 | -1.80% |
| Mar 31, 2019 | 1.30% |